Kazia Therapeutics Annual Report 2021

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the year ended 30 June 2021 2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS Kazia Therapeutics Limited Annual Report 2021 37 Consolidated Note 2021 2020 $ $ Revenue 5 15,182,711 - Other income 6 2,192 995,000 Finance income 42,240 65,905 Expenses Research and development expense (14,541,366) (9,494,328) General and administrative expense (7,021,823) (3,689,867) Fair value losses on financial assets at fair value through profit or loss - (167,814) Loss on revaluation of contingent consideration (2,570,261) (474,557) Loss before income tax benefit (8,906,307) (12,765,661) Income tax benefit 8 484,347 298,195 Loss after income tax benefit for the year attributable to the owners of Kazia Therapeutics Limited (8,421,960) (12,467,466) Other comprehensive income Items that may be reclassified subsequently to profit or loss Net exchange difference on translation of financial statements of foreign controlled entities, net of tax 1,868 (3,520) Other comprehensive income for the year, net of tax 1,868 (3,520) Total comprehensive income for the year attributable to the owners of Kazia Therapeutics Limited (8,420,092) (12,470,986) Cents Cents Basic earnings per share 31 (7.16) (17.07) Diluted earnings per share 31 (7.16) (17.07) The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

RkJQdWJsaXNoZXIy MjE2NDg3